about
Review article: HCV genotype 3 – the new treatment challengePros and cons of liver transplantation in human immunodeficiency virus infected recipients.Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.The role of chemokines in hepatitis C virus-mediated liver diseaseAsunaprevir-containing regimens for the treatment of hepatitis C virus infection.Drug interactions with new hepatitis C oral drugs.ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?Hepatitis C: efficacy and safety in real life.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.
P2860
Q26864571-276AFE84-8A05-4A5A-BFDA-FBBA45EBF17DQ33594879-FABB7568-A8A1-4335-B7B5-480B7E279C45Q38193198-FBC0FF73-6681-4B90-86A3-ACBFAAECFCBCQ38197441-7D0A1028-A7B4-4749-801F-AB36F09A26D8Q38244931-C83078B6-2660-4451-A439-A0E3DD030E06Q38305640-A66C1190-74FC-489F-BA2F-87F000E044E3Q38387667-66180827-7F4B-4592-9D7E-9DC8C1BFCBFDQ38554604-5B4024B7-C315-44E4-A010-E9BC81F50111Q38626467-BBEBB72D-CA24-46CE-BAB8-67726C254993Q38748387-EAF4ED76-9E42-4208-A2B1-BFCF6C313BECQ39010715-884F46E2-BA3A-4B10-8EE9-D42C5A6EC93CQ39040719-72CE91C1-681B-4634-BE86-116F494F1185Q40285894-04D10B43-63FA-42AA-9ED9-EA94F24E683BQ40720542-F84CA0C8-FD46-4479-99E2-08DCB35881BBQ40929061-B7EFAC47-1482-4A9D-BD6B-645C6983BE6CQ41089743-3671C05D-3FC9-4574-87E1-A34289834587Q42196934-4D753034-BBBD-44CB-BD0A-FB0C7404A2A2
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging treatments for hepatitis C.
@en
type
label
Emerging treatments for hepatitis C.
@en
prefLabel
Emerging treatments for hepatitis C.
@en
P2860
P50
P1476
Emerging treatments for hepatitis C
@en
P2093
Anna Parfieniuk-Kowerda
Jerzy Jaroszewicz
P2860
P304
P356
10.1517/14728214.2013.847089
P407
P577
2013-10-08T00:00:00Z